title: Serum levels of soluble interleukin-2 receptor in patients with perennial allergic rhinitis before and after immunotherapy.
abstract: BACKGROUND
  Interleukin-2 receptor (IL-2R) exists in soluble form in sera, and the rate of release of the soluble form of IL-2R (soluble IL-2R) reflects T cell activation in vivo. Since T lymphocytes play a central role in respiratory allergic disorders, the measurement of serum levels of soluble IL-2R may be useful in analyzing the disease state of allergic disorders.
  
  
  OBJECTIVE
  To investigate the serum concentrations of soluble IL-2R in 48 patients with perennial allergic rhinitis and 14 nonatopic healthy controls, with special reference to the possible changes following long-term immunotherapy.
  
  
  METHODS
  This retrospective study included 48 patients who had had variable periods of long-term immunotherapy with Dermatophagoides farinae extracts. The duration of immunotherapy ranged from 5 to 15 years. Serum samples were collected twice from each patient, before the initiation of immunotherapy and at the time of clinical assessment of immunotherapy. All the serum samples were simultaneously used for determination of soluble IL-2R concentrations, by the use of an enzyme-linked immunosorbent assay. To serve as controls, 14 nonallergic subjects of the same age range and sex were chosen.
  
  
  RESULTS
  Patients with allergic rhinitis before immunotherapy had significantly higher serum levels of soluble IL-2R than nonatopic subjects. Elevated serum levels of soluble IL-2R decreased significantly following immunotherapy and the serum levels of soluble IL-2R in patients with allergic rhinitis after immunotherapy were not statistically different from those of nonatopic subjects. In addition, the percent decrease in serum soluble IL-2R correlated significantly with the duration of immunotherapy.
  
  
  CONCLUSIONS
  Hyperactivity of helper T cells of atopic patients is altered after long-term immunotherapy, and such immunoregulatory changes could be theoretically involved in the mechanisms of immunotherapy.
authors.affiliation: Department of Otolaryngology, Osaka City University Medical School, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Ohashi
authors.forename: Y
authors.initials: Y
authors.lastname: Nakai
authors.forename: H
authors.initials: H
authors.lastname: Sakamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Ohno
authors.forename: Y
authors.initials: Y
authors.lastname: Sugiura
authors.forename: H
authors.initials: H
authors.lastname: Okamoto
authors.forename: A
authors.initials: A
authors.lastname: Tanaka
authors.forename: Y
authors.initials: Y
authors.lastname: Kakinoki
authors.forename: K
authors.initials: K
authors.lastname: Kishimoto
authors.forename: M
authors.initials: M
authors.lastname: Hayashi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000032:analysis*; D012189:Retrospective Studies; D012221:Rhinitis, Allergic, Perennial / Q000276:immunology* / Q000628:therapy
chemical_list: D015375:Receptors, Interleukin-2